The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. ARS Pharmaceuticals Inc shares valued at $724,345 were sold by Lowenthal Richard E on Aug 21 ’25. At $14.49 per share, Lowenthal Richard E sold 50,000 shares. The insider’s holdings dropped to 1,196,494 shares worth approximately $16.08 million following the completion of this transaction.
Also, Scott Kathleen D. sold 12,500 shares, netting a total of over 187,500 in proceeds. Following the sale of shares at $15.00 each, the insider now holds 10,042 shares.
Before that, Tanimoto Sarina had sold 37,656 shares from its account. In a trade valued at $530,626, the CHIEF MEDICAL OFFICER traded ARS Pharmaceuticals Inc shares for $14.09 each. Upon closing the transaction, the insider’s holdings decreased to 37,656 shares, worth approximately $16.77 million.
As published in their initiating research note from Scotiabank on March 07, 2025, ARS Pharmaceuticals Inc [SPRY] has been a Sector outperform and the price target has been revised to $30. Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in early February. As of August 20, 2024, Cantor Fitzgerald has initiated its “an Overweight” rating for SPRY. Earlier on August 13, 2024, Raymond James upgraded its rating. Their new recommendation was “a Strong buy” for SPRY stock which previously was a “an Outperform”.
Analyzing SPRY Stock Performance
On last trading session, ARS Pharmaceuticals Inc [NASDAQ: SPRY] plunged -3.24% to $13.44. The stock’s lowest price that day was $13.405, but it reached a high of $13.9987 in the same session. During the last five days, there has been a drop of approximately -7.95%. Over the course of the year, ARS Pharmaceuticals Inc shares have jumped approximately 3.70%. Shares of the company reached a 52-week high of $18.90 on 06/27/25 and a 52-week low of $10.00 on 03/04/25.
Support And Resistance Levels for ARS Pharmaceuticals Inc (SPRY)
According to the 24-hour chart, there is a support level at 13.23, which, if violated, would cause prices to drop to 13.02. In the upper region, resistance lies at 13.82. The next price resistance is at 14.21. RSI (Relative Strength Index) is 32.97 on the 14-day chart, showing neutral technical sentiment.
Is ARS Pharmaceuticals Inc subject to short interest?
Stocks of ARS Pharmaceuticals Inc saw a sharp rise in short interest on 2025-08-15 jumping by 2.9 million shares to 17.77 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 14.86 million shares. A jump of 16.33% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 11.39 of the overall float, the days-to-cover ratio (short ratio) jumped to 11.39.
Which companies own the most shares of ARS Pharmaceuticals Inc (SPRY)?
In terms of ARS Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 22 in the next 12 months, up nearly 58.39% from the previous closing price of $13.89. Analysts anticipate ARS Pharmaceuticals Inc stock to reach 30 by 2025, with the lowest price target being 18. In spite of this, 4 analysts ranked ARS Pharmaceuticals Inc stock as Buy at the end of 2025. On August 12, 2024, Leerink Partners assigned a price target of “an Outperform” to the stock and reiterated coverage with a $20.
